ArticleiScience2026
NR4A3 alleviates diabetic neuropathy via GLS2-mediated mitochondrial repair and Schwann cell differentiation.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic peripheral neuropathy (DPN) is a prevalent complication characterized by Schwann cell dysfunction. The role of the nuclear receptor subfamily 4 group member 3 (NR4A3) in DPN remains unclear. We found that NR4A3 expression is upregulated in the sciatic nerves of streptozotocin (STZ)-induced DPN mice. Overexpression of NR4A3 via AAV9-Mpz-NR4A3 lumbar intrathecal injection improved motor and sensory nerve function and mitigated sciatic nerve pathology. NR4A3 overexpression also reduced oxidative stress and enhanced mitochondrial function. In the high glucose (HG)-induced Schwann cell injury model, NR4A3 overexpression inhibited apoptosis, mitochondrial dysfunction, and dedifferentiation. Integrated ChIP-seq and mRNA-seq profiling identified glutaminase 2 (GLS2) as a direct transcriptional target of NR4A3. NR4A3 binds to the GLS2 promoter and promotes its transcriptional activation, and suppression of GLS2 abrogates the functional protection conferred by NR4A3 in Schwann cells. Together, NR4A3 represents a promising therapeutic target for DPN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.